This diversified cannabis pioneer could make huge moves soon

The cannabis industry seems deeply saturated, so how do you know where to best invest your money? Let’s start with diversification and experience. Founded in 2005, this company serves a diverse and expansive customer base with more than 8,000 retail locations, including licensed cannabis dispensaries, smoke shops, and specialty retailers.

HALO Insider Trading

Insider Trading Chart
Insider Trading History
Frequently Asked Questions
About

Insider Ownership Percentage: 2.40%

Insider Buying (Last 12 Months): $0.00

Insider Selling (Last 12 Months): $8,191,383.70

Halozyme Therapeutics Insider Trading History Chart

Halozyme Therapeutics Share Price & Price History

^$59.84

▼ -2.47 (-3.96%)

As of 09/19/2024 01:45 PM ET

Days: 30 | 90 | 365

Biden’s Capital Gains Tax to Devastate Savings!

From Golden Crest | Ad

Don't let the corrupt elites dictate your future—ACT NOW! This guide is your first step towards financial independence and security.

>> Get Your FREE Wealth Protection Guide <<

Halozyme Therapeutics Insider Trading History

Transaction Date	Insider Name	Title	Buy/Sell	Number of Shares	Average Share Price	Total Transaction	Shares Held After Transaction
9/18/2024	Michael J. LaBarre	SVP	Sell	10,000	$62.03	$620,300.00	173,756
9/12/2024	Helen Torley	CEO	Sell	10,000	$59.20	$592,000.00	676,744
9/10/2024	Helen Torley	CEO	Sell	10,000	$59.09	$590,900.00	676,744
8/21/2024	Michael J. LaBarre	SVP	Sell	10,000	$61.75	$617,500.00	168,176
8/14/2024	Matthew L. Posard	Director	Sell	9,881	$57.70	$570,133.70	69,874
8/12/2024	Matthew L. Posard	Director	Sell	10,000	$55.72	$557,200.00	89,755
7/24/2024	Michael J. LaBarre	SVP	Sell	10,000	$55.12	$551,200.00	168,176
7/22/2024	Nicole Labrosse	CFO	Sell	5,000	$53.93	$269,650.00	15,480
6/27/2024	Nicole Labrosse	CFO	Sell	10,000	$51.93	$519,300.00	15,480
6/11/2024	Matthew L. Posard	Director	Sell	10,000	$50.01	$500,100.00	109,755
5/22/2024	Michael J. LaBarre	SVP	Sell	10,000	$45.38	$453,800.00	168,176
4/17/2024	Michael J. LaBarre	SVP	Sell	10,000	$38.49	$384,900.00	168,176
3/12/2024	Michael J. LaBarre	SVP	Sell	10,000	$41.64	$416,400.00	156,558
2/28/2024	Michael J. LaBarre	SVP	Sell	10,000	$39.55	$395,500.00	156,558
12/12/2023	Michael J. LaBarre	SVP	Sell	10,000	$39.63	$396,300.00	151,911
10/17/2023	Michael J. LaBarre	SVP	Sell	10,000	$36.52	$365,200.00	151,911
9/19/2023	Michael J. LaBarre	SVP	Sell	10,000	$39.10	$391,000.00	151,911
8/31/2023	Helen Torley	CEO	Sell	10,000	$42.82	$428,200.00	623,666
8/29/2023	Helen Torley	CEO	Sell	10,000	$42.40	$424,000.00	623,666
8/22/2023	Michael J. LaBarre	SVP	Sell	10,000	$42.41	$424,100.00	151,911
8/22/2023	Michael J. LaBarre	SVP	Sell	10,000	$42.41	$424,100.00	151,911
8/17/2023	Helen Torley	CEO	Sell	10,000	$43.18	$431,800.00	623,666
8/14/2023	James M. Daly	Director	Sell	10,000	$43.74	$437,400.00	20,503
8/11/2023	James M. Daly	Director	Sell	10,000	$43.71	$437,100.00	30,503
7/26/2023	Helen Torley	CEO	Sell	10,000	$42.69	$426,900.00	623,666
7/18/2023	Michael J. LaBarre	SVP	Sell	10,000	$40.43	$404,300.00	141,911
6/21/2023	Michael J. LaBarre	SVP	Sell	10,000	$36.00	$360,000.00	141,911
4/18/2023	Michael J. LaBarre	SVP	Sell	10,000	$36.00	$360,000.00	141,911
3/9/2023	Helen Torley	CEO	Sell	10,000	$42.73	$427,300.00	623,666
3/7/2023	Helen Torley	CEO	Sell	10,000	$45.47	$454,700.00	623,666
3/1/2023	Jeffrey William Henderson	Director	Sell	10,000	$47.71	$477,100.00	39,045
2/27/2023	Michael J. LaBarre	SVP	Sell	10,000	$49.55	$495,500.00	138,927
2/16/2023	Helen Torley	CEO	Sell	11,061	$49.26	$544,864.86	633,666
2/16/2023	Nicole Labrosse	CFO	Sell	2,525	$49.26	$124,381.50	9,066
2/15/2023	Michael J. LaBarre	SVP	Sell	10,000	$48.39	$483,900.00	143,477
2/8/2023	Helen Torley	CEO	Sell	10,000	$51.36	$513,600.00	587,177
1/19/2023	Helen Torley	CEO	Sell	10,000	$52.41	$524,100.00	587,177
1/17/2023	Michael J. LaBarre	SVP	Sell	10,000	$50.46	$504,600.00	143,137
12/15/2022	Helen Torley	CEO	Sell	10,000	$57.37	$573,700.00	587,177
12/13/2022	Michael J. LaBarre	SVP	Sell	10,000	$58.67	$586,700.00	153,137
12/5/2022	Matthew L. Posard	Director	Sell	10,000	$55.74	$557,400.00	115,189
12/2/2022	Matthew L. Posard	Director	Sell	10,000	$58.80	$588,000.00	125,189
11/17/2022	Helen Torley	CEO	Sell	10,000	$52.15	$521,500.00	587,177
11/15/2022	Michael J. LaBarre	SVP	Sell	10,000	$54.13	$541,300.00	163,137
11/15/2022	Nicole Labrosse	CFO	Sell	5,000	$53.81	$269,050.00	4,045
11/8/2021	Helen Torley	CEO	Sell	50,000	$39.82	$1,991,000.00
11/5/2021	Connie Matsui	Director	Sell	32,000	$40.38	$1,292,160.00
10/4/2021	Helen Torley	CEO	Sell	50,000	$40.09	$2,004,500.00
10/1/2021	Michael J. LaBarre	SVP	Sell	29,450	$39.93	$1,175,938.50

Biden's Successor: The Radical Threat to YOUR Savings!

From Golden Crest | Ad

Kamala Harris isn't just playing politics; she's a serious threat to your financial security. Kamala has a plan to take over your money and leave you with nothing. Higher taxes, government control, and a digital dollar to track every penny you spend. This isn't about convenience; it's about CONTROL.

>> Get Your FREE Wealth Protection Guide <<

SEC Filings (Institutional Ownership Changes) for Halozyme Therapeutics (NASDAQ:HALO)

97.79% of Halozyme Therapeutics stock is owned by institutions. Institutional ownership can be a sign of analyst confidence in the fundamentals of the stock.

Institutional Buying and Selling by Quarter

Halozyme Therapeutics Institutional Trading History

Reporting Date	Hedge Fund	Shares Held	Market Value	% of Portfolio	Quarterly Change in Shares	Ownership in Company
9/5/2024	Sanctuary Advisors LLC	20,528	$1.08M	0.0%	N/A	0.016%
8/21/2024	Truist Financial Corp	84,465	$4.42M	0.0%	-16.7%	0.066%
8/19/2024	Chase Investment Counsel Corp	91,337	$4.78M	1.6%	N/A	0.072%
8/16/2024	Creative Planning	37,291	$1.95M	0.0%	+43.2%	0.029%
8/16/2024	Doheny Asset Management CA	123,560	$6.47M	3.6%	N/A	0.097%
8/16/2024	Algert Global LLC	12,791	$0.67M	0.0%	N/A	0.010%
8/16/2024	Cim Investment Management Inc.	9,142	$0.48M	0.1%	-19.3%	0.007%
8/15/2024	Susquehanna Fundamental Investments LLC	4,000	$0.21M	0.0%	N/A	0.003%
8/15/2024	Scientech Research LLC	19,839	$1.04M	0.2%	+141.5%	0.016%
8/15/2024	Mackenzie Financial Corp	14,779	$0.77M	0.0%	+42.3%	0.012%
8/15/2024	The Manufacturers Life Insurance Company	265,236	$13.89M	0.0%	-0.9%	0.208%
8/15/2024	D. E. Shaw & Co. Inc.	478,775	$25.07M	0.0%	-92.5%	0.376%
8/15/2024	AQR Capital Management LLC	47,773	$2.50M	0.0%	+5.0%	0.038%
8/15/2024	Alpha DNA Investment Management LLC	8,476	$0.44M	0.2%	+27.0%	0.007%
8/15/2024	Caxton Associates LP	25,432	$1.33M	0.0%	N/A	0.020%
8/14/2024	Marietta Investment Partners LLC	28,242	$1.48M	0.3%	N/A	0.022%
8/14/2024	Xponance Inc.	17,762	$0.93M	0.0%	-5.8%	0.014%
8/14/2024	Altshuler Shaham Ltd	27,000	$1.41M	0.0%	N/A	0.021%
8/14/2024	Epoch Investment Partners Inc.	1,436,042	$75.19M	0.3%	+0.2%	1.128%
8/14/2024	ProShare Advisors LLC	31,258	$1.64M	0.0%	-19.2%	0.025%
8/14/2024	Profund Advisors LLC	29,431	$1.54M	0.1%	-28.8%	0.023%
8/13/2024	Hancock Whitney Corp	16,716	$0.88M	0.0%	+207.8%	0.013%
8/13/2024	Ameritas Investment Partners Inc.	39,293	$2.06M	0.1%	-7.1%	0.031%
8/13/2024	Thrivent Financial for Lutherans	942,829	$49.37M	0.1%	-45.0%	0.741%
8/13/2024	Pacer Advisors Inc.	29,446	$1.54M	0.0%	+5.5%	0.023%
8/13/2024	Skandinaviska Enskilda Banken AB publ	927	$49K	0.0%	N/A	0.001%
8/13/2024	Granite Investment Partners LLC	752,839	$39.42M	1.6%	-7.2%	0.592%
8/13/2024	Public Employees Retirement Association of Colorado	13,917	$0.73M	0.0%	-9.5%	0.011%
8/12/2024	Intech Investment Management LLC	22,763	$1.19M	0.0%	N/A	0.018%
8/12/2024	Hsbc Holdings PLC	10,823	$0.57M	0.0%	-91.2%	0.009%
8/12/2024	Vanguard Personalized Indexing Management LLC	20,711	$1.08M	0.0%	+13.5%	0.016%
8/12/2024	Mercer Global Advisors Inc. ADV	3,484	$0.18M	0.0%	N/A	0.003%
8/12/2024	Amalgamated Bank	61,677	$3.23M	0.0%	-10.8%	0.048%
8/12/2024	E Fund Management Co. Ltd.	7,954	$0.42M	0.0%	-23.4%	0.006%
8/10/2024	Mutual of America Capital Management LLC	183,941	$9.63M	0.1%	+31.1%	0.145%
8/9/2024	Edgestream Partners L.P.	39,649	$2.08M	0.1%	-39.3%	0.031%
8/9/2024	Renaissance Technologies LLC	377,580	$19.77M	0.0%	-12.5%	0.297%
8/9/2024	Dimensional Fund Advisors LP	1,897,759	$99.36M	0.0%	+12.4%	1.491%
8/8/2024	Envestnet Asset Management Inc.	229,620	$12.02M	0.0%	+4.9%	0.180%
8/8/2024	Wrapmanager Inc.	6,939	$0.36M	0.1%	-12.7%	0.005%
8/8/2024	O Neil Global Advisors Inc.	4,750	$0.25M	0.1%	N/A	0.004%
8/8/2024	Federated Hermes Inc.	696,131	$36.45M	0.1%	+37.8%	0.547%
8/8/2024	DekaBank Deutsche Girozentrale	57,453	$2.96M	0.0%	+4.6%	0.045%
8/8/2024	Cornercap Investment Counsel Inc.	28,211	$1.48M	0.2%	-0.8%	0.022%
8/8/2024	American Century Companies Inc.	821,266	$43M	0.0%	+9.7%	0.645%
8/8/2024	State of New Jersey Common Pension Fund D	49,177	$2.58M	0.0%	-37.4%	0.039%
8/7/2024	Pier Capital LLC	220,447	$11.54M	1.7%	-1.0%	0.173%
8/7/2024	Doheny Asset Management CA	123,560	$6.47M	5.0%	N/A	0.097%
8/7/2024	Texas Permanent School Fund Corp	121,635	$6.37M	0.1%	+6.0%	0.096%
8/7/2024	Ashton Thomas Private Wealth LLC	3,720	$0.20M	0.0%	N/A	0.003%
8/6/2024	Quest Partners LLC	659	$35K	0.0%	-86.4%	0.001%
8/6/2024	LSV Asset Management	613,800	$32.14M	0.1%	+32.9%	0.482%
8/6/2024	Gallacher Capital Management LLC	7,166	$0.38M	0.2%	-22.5%	0.006%
8/6/2024	Norden Group LLC	16,573	$0.87M	0.2%	+29.3%	0.013%
8/6/2024	Torray Investment Partners LLC	50,748	$2.66M	0.4%	+6.7%	0.040%
8/6/2024	Great Lakes Advisors LLC	83,420	$4.37M	0.0%	-7.4%	0.066%
8/6/2024	Los Angeles Capital Management LLC	116,272	$6.09M	0.0%	-3.9%	0.091%
8/5/2024	Private Advisor Group LLC	22,753	$1.19M	0.0%	+1.8%	0.018%
8/5/2024	Arizona State Retirement System	35,569	$1.86M	0.0%	-2.0%	0.028%
8/3/2024	Kornitzer Capital Management Inc. KS	522,734	$27.37M	0.5%	+7.7%	0.411%
8/3/2024	Chase Investment Counsel Corp	93,777	$5.18M	1.5%	N/A	0.074%
8/3/2024	TD Asset Management Inc	2,365,983	$123.88M	0.1%	-6.9%	1.859%
8/2/2024	Hodges Capital Management Inc.	338,856	$17.74M	1.2%	+6.9%	0.266%
8/2/2024	Mesirow Institutional Investment Management Inc.	289,805	$15.17M	1.3%	-20.4%	0.228%
8/2/2024	Oregon Public Employees Retirement Fund	26,409	$1.38M	0.0%	-19.0%	0.021%
8/1/2024	Rhumbline Advisers	424,496	$22.23M	0.0%	-1.7%	0.334%
8/1/2024	Convergence Investment Partners LLC	26,246	$1.37M	0.4%	N/A	0.021%
8/1/2024	Natixis Advisors LLC	65,099	$3.41M	0.0%	+22.1%	0.051%
8/1/2024	Hussman Strategic Advisors Inc.	42,000	$2.20M	0.6%	+33.3%	0.033%
7/31/2024	nVerses Capital LLC	4,700	$0.25M	0.1%	+161.1%	0.004%
7/31/2024	Mizuho Markets Americas LLC	438,106	$22.94M	0.5%	-4.1%	0.344%
7/31/2024	Van ECK Associates Corp	18,017	$0.94M	0.0%	-1.7%	0.014%
7/31/2024	Commonwealth Equity Services LLC	20,382	$1.07M	0.0%	+34.3%	0.016%
7/30/2024	International Assets Investment Management LLC	639	$33K	0.0%	N/A	0.001%
7/29/2024	Principal Financial Group Inc.	603,058	$31.58M	0.0%	+5.7%	0.474%
7/29/2024	Nations Financial Group Inc. IA ADV	12,919	$0.68M	0.1%	+36.9%	0.010%
7/27/2024	Bernzott Capital Advisors	187,249	$9.80M	4.5%	-10.8%	0.147%
7/26/2024	Legato Capital Management LLC	14,613	$0.77M	0.1%	N/A	0.011%
7/26/2024	Allspring Global Investments Holdings LLC	682,847	$35.75M	0.1%	-1.9%	0.537%
7/26/2024	State of Michigan Retirement System	30,638	$1.60M	0.0%	-5.5%	0.024%
7/26/2024	Shaker Investments LLC OH	66,928	$3.50M	1.5%	+27.0%	0.053%
7/26/2024	EFG Asset Management North America Corp.	140,269	$7.35M	1.3%	+0.1%	0.110%
7/25/2024	Raymond James Trust N.A.	4,689	$0.25M	0.0%	N/A	0.004%
7/25/2024	AMI Asset Management Corp	56,646	$2.97M	0.2%	-58.8%	0.045%
7/24/2024	Argent Capital Management LLC	8,346	$0.44M	0.0%	N/A	0.007%
7/24/2024	Retirement Systems of Alabama	315,095	$16.50M	0.1%	+90.0%	0.248%
7/24/2024	Louisiana State Employees Retirement System	36,000	$1.89M	0.0%	-5.3%	0.028%
7/23/2024	Koa Wealth Management LLC	73,568	$3.85M	3.3%	-1.1%	0.058%
7/23/2024	Shelton Wealth Management LLC	17,533	$0.92M	0.5%	-2.8%	0.014%
7/23/2024	Fifth Third Wealth Advisors LLC	4,296	$0.23M	0.0%	N/A	0.003%
7/22/2024	Fifth Third Bancorp	11,206	$0.59M	0.0%	+2.4%	0.009%
7/20/2024	Washington Capital Management Inc.	10,800	$0.57M	0.5%	-30.3%	0.008%
7/20/2024	China Universal Asset Management Co. Ltd.	14,953	$0.78M	0.1%	-38.6%	0.012%
7/20/2024	First Horizon Advisors Inc.	1,259	$66K	0.0%	-12.9%	0.001%
7/19/2024	Raymond James & Associates	146,261	$7.66M	0.0%	+51.8%	0.115%
7/19/2024	Hoylecohen LLC	4,000	$0.21M	0.0%	N/A	0.003%
7/19/2024	Boston Trust Walden Corp	443,295	$23.21M	0.2%	N/A	0.348%
7/18/2024	Miracle Mile Advisors LLC	4,345	$0.23M	0.0%	N/A	0.003%
7/18/2024	Assenagon Asset Management S.A.	43,950	$2.30M	0.0%	-16.8%	0.035%
7/18/2024	Swedbank AB	332,362	$17.40M	0.0%	-2.9%	0.261%

Data available starting January 2016

Halozyme Therapeutics, Inc., a biopharma technology platform company, researches, develops, and commercializes proprietary enzymes and devices in the United States, Switzerland, Belgium, Japan, and internationally. The company's products are based on the patented recombinant human hyaluronidase enzyme (rHuPH20) that enables delivery of injectable biologics, such as monoclonal antibodies and other therapeutic molecules, as well as small molecules and fluids. It offers Hylenex recombinant, a formulation of rHuPH20 to facilitate subcutaneous (SC) fluid administration for achieving hydration to enhance the dispersion and absorption of other injected drugs in SC urography and to enhance resorption of radiopaque agents; rilpivirine, cabotegravir, and N6LS BNAB for the treatment of HIV; ocrelizumab for multiple sclerosis; XYOSTED, an injection for SC administration of testosterone replacement therapy; and ATRS-1902, a proprietary drug device combination product. The company also provides Herceptin (trastuzumab), Herceptin Hylecta, and Phesgo to treat breast cancer; Mabthera SC for the treatment of chronic lymphocytic leukemia; HYQVIA to treat primary immunodeficiency disorders; and DARZALEX for patients with amyloidosis, smoldering myeloma, and multiple myeloma. In addition, it offers Epinephrine Injection to treat allergic reactions; nivolumab+relatlimab and ANTI-TIM3 for the treatment of solid tumors; ARGX-117 for multifocal motor neuropathy; atezolizumab; nivolumab; afgartigimod; teriparatide injections; and OTREXUP, a SC methotrexate injection for adults with severe active rheumatoid arthritis and severe recalcitrant psoriasis, as well as children with active polyarticular juvenile idiopathic arthritis. Further, the company provides ATRS-1902 for adrenal crisis rescue; ARGX-113; and ARGX-117 to treat severe autoimmune diseases in multifocal motor neuropathy. Halozyme Therapeutics, Inc. was founded in 1998 and is headquartered in San Diego, California.

Today's Range

Now: $59.84

$59.18

$62.48

50 Day Range

MA: $58.14

$51.94

$64.42

52 Week Range

Now: $59.84

$32.83

$65.53

Volume

863,510 shs

Average Volume

1,251,730 shs

Market Capitalization

$7.62 billion

P/E Ratio

24.73

Dividend Yield

N/A

Beta

1.28

Who are the company insiders with the largest holdings of Halozyme Therapeutics?: Halozyme Therapeutics' top insider shareholders include:
Helen Torley (CEO)
Michael J Labarre (SVP)
Matthew L Posard (Director)
Jeffrey William Henderson (Director)
James M Daly (Director)
Nicole Labrosse (CFO)
Learn More about top insider investors at Halozyme Therapeutics.
Who are the major institutional investors of Halozyme Therapeutics?: Halozyme Therapeutics' top institutional investors include:
TD Asset Management Inc — 1.86%
Dimensional Fund Advisors LP — 1.49%
Epoch Investment Partners Inc. — 1.13%
Thrivent Financial for Lutherans — 0.74%
American Century Companies Inc. — 0.65%
Granite Investment Partners LLC — 0.59%
Learn More about top institutional investors of Halozyme Therapeutics stock.
Which major investors are selling Halozyme Therapeutics stock?: Within the last quarter, HALO stock was sold by these institutional investors:
D. E. Shaw & Co. Inc.
Thrivent Financial for Lutherans
TD Asset Management Inc
Hsbc Holdings PLC
AMI Asset Management Corp
Mesirow Institutional Investment Management Inc.
Granite Investment Partners LLC
Renaissance Technologies LLC
In the last year, company insiders that have sold Halozyme Therapeutics company stock include:
Helen Torley (CEO)
Michael J Labarre (SVP)
Matthew L Posard (Director)
Jeffrey William Henderson (Director)
Learn More investors selling Halozyme Therapeutics stock.
Which major investors are buying Halozyme Therapeutics stock?: Within the last quarter, HALO stock was acquired by institutional investors including:
Boston Trust Walden Corp
Dimensional Fund Advisors LP
Federated Hermes Inc.
LSV Asset Management
Retirement Systems of Alabama
Doheny Asset Management CA
Doheny Asset Management CA
Chase Investment Counsel Corp